Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over ...

Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...

The price target adjustment represents an approximately 11% upside potential for Novo Nordisk shares, according to HSBC’s analysis. HSBC cited increased market share estimates for oral semaglutide as ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...